Samuel
Augustine
Professor of Pharmacy Practice
Pharm.D., FAPhA
Pharmacy Practice
Email:
samaugustine@creighton.edu
(402) 280-2756
Advisor:
Academy of Students of Pharmacy (with Dr. Hamilton)
Biography:
Bachelor of Science, Pharmacy University of Nebraska Medical Center, May, 1973, Hospital Pharmacy Residency University of Nebraska Hospital Pharmacy June 1974, Doctor of Pharmacy University of Nebraska Medical Center, May, 1979
Publications:
Scott D, Boyd S, Stephan, M, Augustine S, Reardon, T. Outcomes of Pharmacist-managed Diabetes Care Services in a Community Health Center, Am J Health-Syst Pharm, 63: 2116-2122, 2006.
Boyd S, Scott D, Augustine S: Exercise for low-income patients with diabetes: a continuous quality improvement project. The Diabetes Educator. 32: 385-393, 2006.
Augustine, S, Revision Status of USP Chapter <797> Pharmaceutical Compounding – Sterile Preparations SNM Newsline, J. Nucl Med. 46: 15-16N, 2005.
Augustine, S, Svoboda, A. A Review of USP Chapters <795> and <797> - Their Impact on the Practice of Pharmacy in the State of Nebraska. Nebraska Mortar & Pestle 67, 12, 24-27, 2004.
Augustine, S, Colcher, D, Rutar,F, Norenberg, J, Vang, K, Determination and control of volatilized 131I released in the preparation of 131I tositumomab dosages for radioimmunotherapy. J Am Pharm Assoc. 43: 646-648, 2003
Hohenstein, M, Augustine, S, Rutar, F, Vose,J, Establishing an Institutional Model for the Administration of Tositumomab, Iodine I-131 Tositumomab (Bexxar) Sem in Onc 30: Suppl 4, 39-49, 2003.
Scott, DM, Robinson, DH, Augustine, SC, Roche, EB, Ueda, CT, Development of a Professional Pharmacy Outcomes Assessment Plan Based on Student Abilities and Competencies. Am J Pharm Educ. 66, 357-364, 2002.
Augustine S, Norenberg J, Colcher D, Vose J, Gobar L, Dukat V, Hohenstein M, Rutar F, Jacobson D, Tempero M, The Nuclear Pharmacist’s Role in Tositumomab and I-131 Tositumomab – Combination Therapy for non-Hodgkin’s Lymphoma: Opportunity for Pharmaceutical Care in a Specialty Practice. J Am Pharm Assoc. 42: 93-100, 2002.
Hung, J, Augustine, S, Cheng, K, Green, R, Hopkins, W, Laven, D, Nelson, B, Petry, N, Ponto, J, Quinton, T, Swanson, D: Explanations and Unresolved Issues Pertaining to the Development of the Nuclear Pharmacy Compounding Guidelines, J Am Pharm Assoc. J Am Pharm Assoc. 42, 5, 789-798, 2002.
Augustine SC, Norenberg JP. The treatment of non-Hodgkin’s lymphoma with radiopharmaceuticals. Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals Vol. IX No. 6, 2002.
Rutar, F, Augustine, S, Kaminski, M, Wahl, R, Siegel, J, Colcher, D, Feasibility and Safety of Outpatient Bexxar Therapy (Tositumomab, Iodine I-131 Tositumomab) for Non-Hodgkin’s Lymphoma Based on the Radiation Doses to Family Members. Clin Lymph 3: 164-172, 2001
Goel, A., Baranowska-Kortylewicz, J., Hinrichs, S, Wisecarver, J, Pavlinkova, G., Augustine, S., Colcher, D., Booth, B, and Batra, S. K. 99m Tc-Labeled Divalent and Tetravalent CC49 single-chain Fvs: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma . J. Nucl Med. 42:1519-1527, 2001.
Rutar, F, Augustine, S, Colcher,D, Siegel, J, Jacobson, D, Tempero, M, Dukat,V, Hohenstein, M, Gobar, L, Vose,J, Outpatient Treatment with 131I-Anti-B1 Antibody: Radiation Exposure to Family Members. J Nucl Med. 42: 907-915, 2001.
Goel, A., Augustine, S., Baranowska-Kortylewicz, J., Colcher, D., Booth, B. J. M.,Pavlinkova, G., Tempero, M., and Batra, S. K. Single-dose versus fractionated radioimmunotherapy of human colon carcinoma xenografts using 131I-labeled multivalent CC49 single-chain Fvs. Clin. Cancer Res.7: 175-184, 2001.
Hung, J, Augustine, S, Cheng, K, Green, R, Hopkins, W, Laven, D, Nelson, B, Petry, N, Ponto, J, Quinton, T, Swanson, D: The Nuclear Pharmacy Compounding Guidelines. American Pharmaceutical Association, Washington D.C., 2001.
Goel, A., Colcher, D., Baranowska-Kortylewicz, J., Augustine, S., Booth, B. J. M., Pavlinkova, G., and Batra, S. K. Genetically-engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 60: 6964-6971, 2000.
Tempero, M, Leichner, P, Baranowska-Kortylewicz, J, Harrison, K, Augustine, S, Scholm, J, Anderson, J, Wisecarver, J, Colcher, D, High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial, Clin. Cancer Res., 6: 3095-3102, 2000.
Vose,J, Colcher,D, Gobar,L, Bierman,P, Augustine,S, Tempero,M, Leichner,P, Lynch,J, Goldenberg,D, Armitage,J, PhaseI/II Trial of Multiple Dose Iodine-131 Mab LL2 (CD22) in Patients with Recurrent non-Hodgkin’s Lymphoma. Leukemia and Lymphoma 38; 91-101, 2000.
Instructor in:
PHA 313 Pharmacy Calculations
PHA 485&486 Dispensing and Pharmaceutical Care
PHA 344 Parenteral Drug Products
Research Interests:
Radioimmunotherapy,
Nutriceuticals, Parenteral Products
office:
Rm 153 HLSB, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, NE 68178
office_hrs:
By Appointment
Fax:
(402) 280-1268
Pager:
|